Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Vaxart accelerates Ebola tablet vaccine development Vaxart, a privately held company developing vaccines that are administered by tablet rather than by injection, has announced that the company is accelerating its Ebola tablet vaccine program.
Drug Research > Drug Discovery & Development > News
MabVax Therapeutics nominates HuMab 5B1 as lead clinical development candidate MabVax Therapeutics Holdings, a clinical stage oncology drug development company, has formally nominated its HuMab 5B1 antibody as a clinical candidate for the diagnosis and treatment of pancreatic and colon cancer.
Drug Research > Drug Discovery & Development > News Immunotech completes negotiations with Uldic to market potential Ebola treatment in Africa By PBR Staff Writer
Immunotech Laboratories has completed negotiations with Zimbabwe-based Uldic Investment (Uldic) to pursue the development of market opportunities related to potential treatment of the deadly Ebola virus in Sub-Saharan West Africa.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Apricus expands development pipeline with in-licensing of US rights for fispemifene
Apricus Biosciences has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator ("SERM"), fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland.
Drug Research > Drug Discovery & Development > News
EYLEA injection shows better gains in visual acuity than both bevacizumab and ranibizumab in NIH-sponsored DME study
Regeneron Pharmaceuticals, has announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both bevacizumab (Avastin/Genentech) and ranibizumab injection (Lucentis/Genentech), the primary endpoint of the study.
Drug Research > Drug Discovery & Development > News
GSK update on current development status of the GSK/NIH Ebola vaccine candidate
With the Ebola crisis in West Africa continuing, GSK is working closely with the World Health Organization (WHO), regulators and other partners to respond to the outbreak, to accelerate development of our investigational Ebola vaccine and to ramp up production as quickly as possible.
Drug Research > Drug Discovery & Development > News
FDA approves abuse deterrent labeling for Pfizer's Embeda
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved an updated label for Pfizer's Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies.
Drug Research > Drug Discovery & Development > News
NeuroSigma, US Veterans Administration (VA) enter into cooperative research and development agreement
NeuroSigma a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, Pharmacyclics and Janssen collaborate for new non-hodgkin lymphoma drug
By PBR Staff Writer
Bristol-Myers Squibb (BMS), Pharmacyclics and Janssen Research & Development have entered into collaboration to conduct a Phase I/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination of Opdivo and Imbruvica in patients with non-Hodgkin lymphoma (NHL).
Drug Research > Drug Discovery & Development > News
HemoShear completes initial development phase of new cancer drug discovery platform
By PBR Staff Writer
HemoShear has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations.
Drug Research > Drug Discovery & Development > News
Pharmaceutical firms to use UC San Diego-led resource to share data for drug design
By PBR Staff Writer
Pharmaceutical companies will collaborate with researchers at the University of California, San Diego to provide previously unreleased proprietary data for drug discovery through a new $3.7m effort funded by the National Institutes for Health.
Drug Research > Drug Discovery & Development > News
Blaze Bioscience gets SBIR phase II funding for clinical trial of tumor paint BLZ-100 in sarcoma
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, has been awarded a $1.5m Small Business Innovation Research (SBIR) Phase II contract from the National Cancer Institute (NCI) to study Tumor Paint BLZ-100 in patients with soft tissue sarcoma.
Drug Research > Drug Discovery & Development > News
EMD Serono, ICR, Wellcome Trust collaborate to develop anti-cancer drugs
By PBR Staff Writer
Merck subsidiary EMD Serono, the Institute of Cancer Research (ICR) and the Wellcome Trust have entered into a co-development and license agreement for developing new drug candidates to treat different forms of cancer.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250